T/R potency <5% [Regulatives / Guidelines]

posted by Achievwin – US, 2022-09-07 22:50 (619 d 17:25 ago) – Posting: # 23277
Views: 2,573

❝ ❝ Somewhere in the Bioequivalence guidance I remembered that when designing the studies we try to keep T/R potency +/-5%. Can someone point out where this kind of condition existed, (latest guidance has no mention of this)


❝ – AFAIK, it was never stated by the FDA in any guidance.


It was there in 2001 guidance as desired requirement-not mandatory... problem is that I can not find that 2001 (first) BE/BA guidance
I can not find that 2001 (first) BE/BA guidance. Also in 2021 guidance lines 807-808

Complete thread:

UA Flag
Activity
 Admin contact
23,029 posts in 4,834 threads, 1,644 registered users;
29 visitors (0 registered, 29 guests [including 6 identified bots]).
Forum time: 16:15 CEST (Europe/Vienna)

We must be careful not to confuse data with the abstractions
we use to analyze them.    William James

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5